PEDIATRICS Vol. 106 No. 2 August 2000, p. e28
ELECTRONIC ARTICLE:
Chickenpox Attributable to a Vaccine Virus Contracted From a
Vaccinee With Zoster
From Ahmanson Pediatrics Department, Cedars Sinai Medical Center, Los Angeles, California; and the Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
| |
ABSTRACT |
|---|
|
|
|---|
Five months after 2 siblings were immunized with varicella vaccine, 1 developed zoster. Two weeks later the second sibling got a mild case of chicken pox. Virus isolated from the latter was found to be vaccine type. Thus, the vaccine strain was transmitted from the vaccinee with zoster to his sibling. Vaccinees who later develop zoster must be considered contagious. varicella-zoster, zoster, vaccine, transmission, rash, PstI.
Varicella is the initial manifestation of varicella-zoster
virus (VZV) infection. After clinical recovery, as with other herpes viruses, VZV persists in a latent form. The virus may become activated resulting in zoster. This occurs most commonly in older individuals, but also is seen in immunocompromised younger people, eg, those infected with human immunodeficiency disease virus or transplant recipients. It also is known to occur in normal varicella vaccine recipients.1
Exposure of susceptible individuals to zoster has been recognized for
more than a century to result in varicella.2 We now report
the occurrence of varicella in a child whose brother developed zoster
after immunization with varicella vaccine. It has been advised that
vaccinees that develop a rash soon after immunization avoid contact
with persons at high risk for complications of varicella.3
Similar precautions would be appropriate for contact with vaccinees that develop zoster. Heretofore, transmission of vaccine virus was
recognized to occur primarily from vaccinees with leukemia that
developed rashes after immunization.4,5 Although far less
common, vaccine virus also has spread from normal vaccinees
with,6,7 and possibly without, a rash.8
Clinical Observations
Five months after receipt of varicella vaccine a 3-year-old boy
who was otherwise normal was noted to have thoracic zoster. Fourteen
days later, his healthy normal brother, who had been immunized at the
same time as he was, developed a mild case of varicella. On the second
day of his illness, he was observed to have ~50 vesicular lesions in
a generalized distribution on the trunk and scalp. He was playful and
did not seem to be very ill. Their mother had not had varicella during
her pregnancy and the brothers had no known exposure to varicella
except for contact 3 days before their immunization with a child who
had the onset of rash 3 days later.
Virologic Studies
Human embryonic diploid fibroblast cultures were inoculated with
vesicular fluid collected from the child with varicella. Focal
cytopathic changes characteristic of VZV were observed 4 days later.
DNA was extracted from the isolate and the region flanking the
PstI site was amplified by polymerase chain reaction, using
appropriate primers.9 The products were separated on an
agarose gel.
The occurrence of zoster in normal varicella vaccine recipients is
well-recognized.1 Thus, there did not seem to be any
reason to investigate the sibling who developed zoster. The risk of
normal children developing zoster after immunization has been reported
to be no greater than if they had had varicella rather than being
immunized.10 Children with leukemia who have received the
vaccine seem to be less likely to develop zoster than leukemic children
who have had chicken pox.11,12
It was important to establish whether a vaccine or wild strain of VZV
had caused varicella, although there was no known exposure likely to
have caused infection. If it were a wild strain, one might have
attributed the child's chickenpox to infection from an unrecognized
exposure. Wild strain has been isolated from a vaccinee who developed
zoster, which apparently resulted from reinfection with wild type
VZV.13 In this case, it was the wild strain rather than
the vaccine strain that became activated and produced zoster.
In 1987, we observed that digestion of VZV DNA with a restriction
enzyme PstI could distinguish wild types from vaccine types of virus.5 Restriction enzymes, eg, PstI, have
very specific target substrates, and changes in the base sequences
where the enzyme acts will affect its ability to digest the viral DNA
strand. A change in the base sequence in vaccine strains at the site
where PstI cuts wild strains makes it impossible for
PstI to cut vaccine strains. Thus, the wild type will have 2 fragments after PstI treatment, while the vaccine strain
will remain uncut in this region and have a single fragment. When the
products of PstI treatment are separated on a gel, a single
fragment will be found in vaccine strains that is approximately twice
the size of the corresponding 2 fragments obtained from wild strains
(Fig 1).
![]()
METHODS
Top
Abstract
Methods
Discussion
References
![]()
DISCUSSION
Top
Abstract
Methods
Discussion
References

View larger version (66K):
[in a new window]
Fig. 1.
Polymerase chain reaction analysis of the patient's isolate, compared
with wild strains and vaccine strains of VZV. The polymerase chain
reaction products are separated by gel electrophoresis. Lane 1 is the
Oka vaccine strain; lane 2, a US wild strain (Emily); lane 3, the
isolate from the sibling who developed varicella. The Oka strain and
the isolate both have changes in the bases in the region where
PstI digests the wild type virus. Thus,
PstI is unable to digest the vaccine or isolate, so
there is only a single 349-kb band. The wild strain, which contains the
PstI site, is split into 2 fragments, both of which are
smaller (99 kb and 250 kb) than the single nonsplit fragment from the
Oka or isolate strains.
The illness in the child who developed varicella after exposure to his brother with zoster was very mild, as are most breakthrough cases of chicken pox resulting from wild virus.14 It has been assumed that these vaccinees may have some residual protection from their previous immunization.
However, children who have been immunized previously generally do not develop a rash after exposure to a vaccine-induced rash. This would suggest that the child who developed chickenpox may not have had a take from his immunization, and thus, may have been susceptible to VZV at the time of exposure to zoster. Infection of susceptible normal individuals with vaccine virus is expected to result in mild illness.4,5 Alternatively, vaccinees who develop zoster may be more likely to transmit VZV to contacts than vaccinees who develop a varicella-like rash shortly after immunization.
The risk of a vaccinee who develops zoster infecting contacts is not known. The likelihood of transmission of vaccine virus to contacts of vaccinees has been reported to be related to the number of skin lesions that develop after immunization.4 In a study of transmission of vaccine virus from children with leukemia to susceptible household members, only vaccinees who developed a rash infected contacts. None of the 56 subjects exposed to vaccinees without rash seroconverted, whereas 2 of 7 subjects exposed to vaccinees with rash seroconverted.5 Whether vaccinees develop zoster or a rash after immunization, they pose a potential hazard to individuals at high risk to develop complications of chickenpox. Thus, the same caveat of avoiding exposure to vaccinees with a postvaccination rash3 also pertains to vaccinees who subsequently develop zoster. In the case reported, the child with zoster infected his normal sibling.
| |
ACKNOWLEDGMENTS |
|---|
We thank Drs Stephen E. Straus, Jeffrey Cohen, and Phillip Krause for their helpful suggestions.
| |
FOOTNOTES |
|---|
Received for publication Sep 24, 1999; accepted Mar 17, 2000.
Reprint requests to (P.A.B.) National Institutes of Health, National Institute of Allergy and Infectious Diseases, Bldg 10, Room 11N228, 9000 Rockville Pike, Bethesda, MD 20892. E-mail: pbrunell{at}niaid.nih.gov
| |
ABBREVIATIONS |
|---|
VZV, varicella-zoster virus.
| |
REFERENCES |
|---|
|
|
|---|
- Centers for Disease Control and Prevention Prevention of varicella updated. MMWR CDC Surveill Summ 1999; 48:1-5 [Medline]
- Bokay J Das Austreten ser Schafblattern unter besonderen Umstanden. Ungar Arch f Med Wiesb 1892; 1:159-161
- Centers for Disease Control and Prevention Prevention of varicella. MMWR CDC Surveill Summ 1996; 45:1-36 [Medline]
- Tsolia M, Gershon AA, Steinberg SP, Gelb L Live attenuated varicella vaccine: evidence that the virus is attenuated and the importance of skin lesions in transmission of varicella-zoster virus. J Pediatr 1990; 116:184-189 [CrossRef][Medline]
- Brunell PA, Geiser CF, Novelli V, Lipton S, Narkewicz S Varicella-like illness caused by live varicella vaccine in children with acute lymphocytic leukemia. Pediatrics 1987; 79:992-927
- LaRussa P, Steinberg S, Meurice F, Gershon A Transmission of vaccine strain varicella-zoster virus from a healthy adult with vaccine associated rash to susceptible household contacts. Infect Dis 1997; 176:1072-1075
- Saltzman M, Sharrar R, Steinberg S, La Russa P Transmission of varicella-vaccine virus from a healthy 12 month old child to his pregnant mother. J Pediatr 1997; 131:151-154 [CrossRef][Medline]
-
Weibel RE,
Kuter BJ,
Neff BJ,
Live Oka/Merck varicella vaccine in healthy children.
JAMA.
1985;
254:2435-2439
[Abstract/Free Full Text] -
LaRussa P,
Lungu O,
Hardy I,
Gershon A,
Steinberg S,
Silverstein S
Restriction fragment length polymorphism of polymerase chain reaction products from vaccine and wild type varicella-zoster virus isolates.
J Virol
1992;
66:1016-1020
[Abstract/Free Full Text] - Plotkin SA, Starr SE, Connor K, Morton D Zoster in normal children after varicella vaccine. J Infect Dis 1989; 159:1000 [Medline]
-
Brunell PA,
Taylor-Wiedeman J,
Geiser C,
Frierson L,
Lydick E
Risk of herpes zoster in children with leukemia: varicella vaccine compared with history of chickenpox.
Pediatrics
1986;
77:53-56
[Abstract/Free Full Text] - Hardy I, Gershon, AA, Steinberg SP, LaRussa P The incidence of zoster after immunization with live attenuated varicella vaccine: study in children with leukemia. Varicella Vaccine Collaborative Study Group. N Engl J Med 1991; 325:1545-1550 [Abstract]
- Gelb L, Dohner DE, Gershon AA, Molecular epidemiology of live attenuated varicella virus vaccine in children with leukemia and in normal adults. J Infect Dis 1987; 155:633-640 [Medline]
-
Watson B,
Piercy S,
Plotkin S,
Starr S
Modified chicken pox in children immunized with the Oka/Merck varicella vaccine.
Pediatrics
1993;
91:17-22
[Abstract/Free Full Text]
Pediatrics (ISSN 0031 4005). Copyright ©2000 by the American Academy of Pediatrics
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||




